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We are the music makers, 
And we are the dreamers of dreams, 
Wandering by lone sea-breakers, 
And sitting by desolate streams; — 
World-losers and world-forsakers, 
On whom the pale moon gleams: 
Yet we are the movers and shakers 
Of the world for ever, it seems. 
 
With wonderful deathless ditties 
We build up the world's great cities, 
And out of a fabulous story 
We fashion an empire's glory: 
One man with a dream, at pleasure, 
Shall go forth and conquer a crown; 
And three with a new song's measure 
Can trample a kingdom down. 
 
We, in the ages lying, 
In the buried past of the earth, 
Built Nineveh with our sighing, 
And Babel itself in our mirth; 
And o'erthrew them with prophesying 
To the old of the new world's worth; 
For each age is a dream that is dying, 
Or one that is coming to birth. 
 
Ode by Arthur O'Shaughnessy 
 
 
  
ABSTRACT 
STAT3 is one of the seven family members of the STAT transcription factor family. STAT3 
has become a very attractive target for cancer therapy and other diseases. It has a prominent 
role in cancer development as well as progression. However, there are still no STAT3 
inhibitors applied in the clinic. One of the underlying reasons might be the complicated 
regulation of STAT3 function. Not only do many signaling pathways converge on STAT3, it 
is also a redox sensitive transcription factor. Therefore, STAT3 activity is determined by a 
plethora of different intracellular and extracellular signals. STAT3 also affects many different 
cellular functions and has a role in each hallmark of cancer, either through its role as a 
transcription factor or through one of its diverse non-transcriptional functions. 
This thesis focuses on the STAT3 small molecule inhibitor field, by trying to further explore 
the mechanism of action of novel and widely used STAT3 inhibitors. In addition, we 
developed a new method to discover specific STAT3 inhibitors. Interestingly, we found that 
STAT3 was not targeted directly, but rather STAT3 is inactivated due to oxidation of cysteine 
residues on the protein. 
In Paper I, we developed a cell-based high-throughput screening system to evaluate STAT3 
transcriptional activity. This was used to screen 28.000 compounds, where after several 
additional screening steps four lead compounds were selected for further evaluation. All four 
compounds inhibited STAT3 transcriptional activity. Their mechanisms of action however 
appeared to be diverse. One compound, KI16, was found to preferentially inhibit STAT3 
function compared to STAT1, and inhibited STAT3-driven phenotypes. 
In Paper II, we used differential scanning fluorimetry (DSF) to highlight some of the 
shortcomings of other in vitro STAT3 inhibitor methods. Two STAT3 protein truncations 
were used to evaluate SH2 domain binders of STAT3 as well as binding specificity of well-
known STAT3 small molecule inhibitors. Phosphopeptides were able to specifically bind to 
the STAT3 SH2 domain and increase protein thermal stability. While two small molecule 
inhibitors did not affect thermal stability of either truncation, two other small molecules, 
Stattic and BP1-102 decreased stability of both truncations. Which was an indication that 
both small molecules are not specific SH2 domain binders, but rather target STAT3 in 
multiple sites leading to its destabilization. 
In Paper III, we performed structure-activity relationship (SAR) on a selected series of 
compounds that were identified in the high-throughput screening in Paper I. Sub 1 µM 
compounds were generated that potently inhibited STAT3 transcriptional activity. These 
compounds were found to have electrophilic properties, which were essential for STAT3 
inhibition. With the use of a fluorescently-tagged compound we were able to pinpoint the 
cellular protein target, thioredoxin reductase 1 (TrxR1). The top compounds as well as Stattic 
were potent inhibitors of TrxR1 function, and were found to induce oxidative stress. Vice 
versa, TrxR1 inhibitors were also able to inhibit STAT3 transcriptional activity. Oxidative 
stress induction leads to the oxidation of Prx2, which can relay its oxidative equivalents to 
STAT3 that forms oxidized dimers and is transcriptionally inactivated. TrxR1 is the main 
reductase that reduces Prx2 and STAT3 through consumption of NADPH. However due to 
the compounds inhibiting its function, the proteins remain oxidized, and eventually leads to 
cell death. 
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1 INTRODUCTION 
1.1 CANCER THERAPY DEVELOPMENT 
Cells are the building blocks of tissues, constituting organs, which form functional systems, 
allowing a multicellular organism to become a complex functioning being. In order to keep 
this complexity organized, on a cellular level processes like cell division, cell death and 
metabolism need to be tightly controlled 1. Cancer is defined by the loss of this control 
thereby allowing cells to divide unregulated. The disease itself is easily defined, but because 
the underlying cause is different per patient, the development, therapeutic response and 
clinical outcome are as well 2. Consequently, it is very difficult to find the appropriate 
treatment for each patient.  
Long after surgery and radiotherapy dominated cancer therapy, the field of 
chemotherapeutics was initiated. After the development of tumor model systems, 
transplantable tumors in rodents, the field started to advance. There were initial failures with 
drug screenings, however it was Charles Huggins who introduced hormonal therapy when he 
treated prostate cancer patients with hormones, earning him a Nobel Prize. Of course as many 
other big discoveries were found by accident, the first observation that kick started the testing 
of chemotherapeutic small molecule drugs came during the Second World War. An 
accidental spill of sulfur mustards on troops in Bari Harbor, Italy led to the discovery that the 
soldiers exposed had their bone marrow and lymph nodes significantly depleted. This led to 
the administration of nitrogen mustard to patients with non-Hodgkin’s and other lymphomas, 
resulting in tumor regression 3. This paved the way for synthesis and testing of related 
alkylating agents, such as Chlorambucil and Cyclophosphamide 4. Around the same time the 
first antimetabolite was developed, the folic acid antagonist, methotrexate, and antitumor 
antibiotics as well, e.g. Actinomycin D. In the wake of these discoveries many different types 
of chemotherapeutics have been developed, the major groups being: alkylating agents, plant 
alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors and others 4.  
Early observations led to other sophisticated ways to treat specific tumors. Instead of 
systemic chemotherapeutics, targeted therapy is based on specific traits of tumors. 
Radioactive Iodine-131 for thyroid cancer patients was one of the first targeted therapies 5. A 
more famous example is Tamoxifen targeting ER in breast cancer 6. However, the first 
breakthrough discovery for molecular targeted therapy was Imatinib 7. It was designed to 
target BCR-ABL fusion kinase in chronic myeloid leukemia (CML). BCR-ABL is the result 
of a specific chromosomal translocation of chromosome 9 and 22. It significantly improved 
survival and clinical outcome for CML patients since its FDA approval in 2001 8. This 
exploded the targeted therapy research and many small molecules and monoclonal antibodies 
have been approved for clinical use since, targeting specific oncogenes and kinases, e.g. 
EGFR, HER2, ALK, PARP, PI3K, VEGFR, PDGFR, Braf, MEK, CDK etc.  
The importance of reactive oxygen species (ROS) and if their levels are higher in cancer cells 
has been a research topic under debate for many years. ROS are free radical and non-radical 
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oxygen species through derivation of oxygen 9. In tolerable levels they have been shown to 
affect essential biological processes, e.g. proliferation, differentiation, migration and cellular 
signaling 10. If there aren’t enough cellular antioxidants to counteract the ROS, oxidative 
stress is induced, leading to DNA and other cellular damages, promoting oncogenesis 11. 
Therefore, high basal levels of ROS are associated with oncogenesis. More important, the 
high cellular energy upkeep cancer cells demand in order to keep dividing also increases 
cellular oxidative stress 12. In order to cope, oncogenes drive the expression of more 
antioxidants and subsequent elimination. This upward shift in the redox balance has been 
suggested to make cancer cells more sensitive to sudden increases in oxidative stress leading 
to selective cell death 12. Interestingly, one of the main mechanisms of many chemotherapies 
and radiotherapy is their associated induction of oxidative stress 13,14.  
 
1.2 IL6 SIGNALING IN CANCER 
The cytokine Interleukin 6 (IL6) has a pleiotropic effect on immune response, inflammation 
and hematopoiesis. It was named BSF-2 for its ability to induce activated B-cells into 
antibody-producing cells, IFN-β2 for its antiviral activity, HPGF owing to its enhancement of 
fusion cell growth of plasma and myeloma cells, and HSF for its effect on acute phase protein 
synthesis in hepatocytes 15–19. When BSF-2 cDNA was cloned in the lab of Kishimoto 
however, it was discovered that all these molecules were all the same gene. Henceforth the 
molecule has been named IL6 20. It is synthesized and can be secreted by many different cell 
types, including fibroblasts, T-cells and monocytes 21. The classical pathway of IL6 signaling 
commences with IL6 binding to its receptor IL6R 22. This receptor is mainly expressed on the 
membrane of specific immune cells and hepatocytes, but the receptor can be proteolytically 
cleaved and become a soluble factor as well 23. The complex of cytokine and receptor has the 
capacity to bind to gp130 receptor, which is ubiquitously expressed on cells. These receptors 
form a heterotetramer, which can activate several downstream signaling pathways: 
Ras/MAPK. PI3K/Akt and JAK/STAT are all activated through gp130 tyrosine 
phosphorylation and drive cell proliferation and survival 24. 
IL6 plays a role in many autoimmune diseases. Persistent IL6 signaling has been related to 
rheumatoid arthritis, arterosclerosis, asthma and lupus 25. And persistent signaling has been 
shown to facilitate different facets of oncogenesis, progression and drug resistance 26. IL6 and 
IL6R targeting drugs only have shown their clinical efficacy in rheumatoid arthritis (RA) and 
Castleman’s disease, where Tocilizumab and Siltuximab were shown to have a beneficial 
effect over placebo treatment 27. However, in various cancer types they have no demonstrated 
clinical efficacy 24. This is not due to ineffectiveness of the drug, since it efficiently inhibits 
IL6 driven production of C-reactive protein (CRP) in vivo by hepatocytes of cancer patients 
24,28. Lack of efficacy is more likely due to cancer cell plasticity, and the multiple downstream 
signaling effects that IL6 inhibition has in cancer cells.  
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1.3 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) 
The protein family of STATs was discovered during the exploration of IFN-α and IFN-γ 
signaling specificity 22,29. The family is comprised of STAT1, STAT2, STAT3, STAT4, 
STAT5a, STAT5b and STAT6 30. These predominantly cytoplasmic transcription factors 
were found to be phosphorylated on a tyrosine residue located around amino acid 700. It was 
later found that other receptors are also able to catalyze this tyrosine phosphorylation, e.g. 
growth factor receptors (EGFR, FGFR, PDGFR) and gp130 receptor complexes (IL6R, 
OSMR, LIFR), other cytokine receptors and non-receptor Tyrosine kinases 31. Several 
STATs also contain a Serine residue further down the transactivation domain, which also can 
be phosphorylated 30. Phosphorylation of this residue contributes to the transcriptional 
activity of STATs and was shown to influence non-transcriptional functions of STAT3 32–34.  
 
Figure 1. STAT family member structural domains. A. The general structural domains of 
all the STAT family members. The transactivation domain interlinks two monomers to form 
an activated dimer upon tyrosine phosphorylation. Serine phosphorylation enhances 
transcriptional activity. B. Surfaces of resolved crystal structures of STAT3 domains, colors 
correspond to the domains in A. Full length STAT3 protein was never resolved due to the 
inherent flexibility of transactivation domain, as well as the connection between N-terminal 
and Coiled-coil domain. The N-terminal domain alone and unphosphorylated STAT3β core 
protein (bound to DNA target sequence oligo (omitted)) crystal structures were resolved 
separately 35–37. 
 
There is a lot of homology between the STAT family members. Each member is comprised 
of five structural domains: an N-terminal, coiled-coil, DNA-binding, Linker, Src homology 2 
(SH2) domain and transactivation domain (Figure 1) 30. The canonical pathway of activation 
is also similar for all members 22,30. An extracellular signaling molecule, like IL6 described 
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above, binds its membrane receptor, which leads to receptor homodimerization and 
autophosphorylation of Janus Kinases (JAKs). JAKs in-turn phosphorylate tyrosine residues 
on the intracellular domain of the receptor. This enables STATs to bind to the receptor and 
become phosphorylated. When activated, STATs form homo- or heterodimers with other 
family members and translocate to the nucleus, where they bind directly to DNA consensus 
sequences or cooperate with other transcription factors to regulate gene transcription (Figure 
2). The functions of different STATs are rather particular and quite diverse 22,30. The specific 
functions of STAT3 and its close family members, STAT1, STAT5a and b play an important 
role in cancer 38,39. 
 
Figure 2. Depiction of the cellular IL6/JAK/STAT3 activation pathway. Two IL6 
molecules bind to IL6R, forming a heterotetrameric structure with GP130 in the plasma 
membrane. This stimulates the autophosphorylation of JAKs, localized on the intracellular 
domain of gp130. JAKs phosphorylate tyrosine residues on the intracellular domain of gp130, 
which in turn phosphorylate STAT3. This drives STAT3 dimerization and consecutive 
transport to the nucleus, where transcription of target genes is initiated. 
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1.3.1 STAT1 
Cellular antiviral, immunological and antiproliferative responses are mainly regulated by 
IFNs 40–42. IFNs stimulate the activation of STAT1, driving the cellular immune response 
towards viral infection clearance 43. STAT1 knockout mice lack selective signaling in their 
response to IFN stimulation, causing high sensitivity towards infection by viral and microbial 
infections 44,45. Context and cell-type are key elements when exploring the functions of all 
STATs. In this respect, STAT1 has been found to have tumor suppressive and tumor 
supporting functions 46. A precautionary note, many studies have performed correlation 
studies of protein levels of total STAT1, unphosphorylated STAT1, pSTAT1, and STAT1 
mRNA levels. While STAT1 localization and expression can both determine its 
transcriptional function in cancer. Both parameters should be taken into consideration when 
exploring contradictory reports on STAT1. 
Its suppressive function was described in STAT1 knockout mouse models. In the absence of 
tumor suppressor p53, STAT1 depletion curtailed spontaneous tumor development time 47. 
Deletion of STAT1 led to more rapid mammary tumor development with concomitant 
expression of ErbB2/neu oncogene 48. STAT1 deletion also increased spontaneous mammary 
adenocarcinoma formation in female mice 49. These studies have established STAT1 as a 
tumor suppressor in cancer cells and the tumor microenvironment. The established role of 
STAT1 in signaling of all IFNs has elucidated its role in cell cycle inhibition, protein 
expression stimulating apoptosis, as well as other forms of cell death induction 50. STAT1 
represses the transcription factor c-myc, which stimulates cell cycle progression 51. 
Additionally, STAT1 drives the expression of CDK inhibitors p21 and p27, or induces cell 
cycle arrest through direct interaction with Cyclin D1-3 or CDK4 in fibrosarcoma 46,52,53.  
It is rather conflicting however that STAT1 also has multiple tumor supporting functions. 
STAT1 expression levels as well as activation levels correlated with poor patient prognosis in 
breast cancer and sarcoma patients 54,55. STAT1 mRNA and pSTAT1 levels however not 
always correlated in those studies, and therefore STAT1 activity was also correlated with a 
favorable prognosis 54,56–60. Gene expression profiling of radioresistant squamous cell 
carcinoma cells that activated STAT1 signaling revealed that mainly IFN-stimulated genes 
were highly expressed. The profile was termed IFN-related DNA damage resistance signature 
(IRDS) 61. IRDS induction was detected in different xenograft models of breast, as well as 
head and neck cancer 62,63. High IRDS also correlated with poor prognosis in glioblastoma 
patients 64. Different mechanisms have been described to confer STAT1-induced therapy 
resistance. STAT1 knockdown cells were shown to alter the expression of genes involved in 
cellular metabolism, while another study reported a STAT1-dependent upregulation of 
HDAC4 and the P-glycoprotein 1 (MDR1) gene, regulating multidrug resistance 65,66. STAT1 
was also shown to mediate immune evasion of tumor cells. STAT1, in combination with 
STAT3, drives the expression of programmed death-ligand 1 (PD-L1) expression on tumor 
cells, whereby cytotoxic T-cell and NK cell functions are impeded 67. Inhibition of either 
STAT1, or STAT3 leads to partial downregulation of PD-L1 expression, while inhibition of 
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both abolished PD-L1 expression completely. STAT1 and STAT3 moreover form 
heterodimers that induce gene transcription 68. 
1.3.2 STAT3 
Mouse studies have revealed that knockouts of STAT genes generate rather specific 
phenotypes, where each STAT could be linked to a relatively discrete pathway 69. Unlike its 
family members, STAT3 knockout causes embryonic lethality 70. STAT3 is activated in 
response to a platitude of cytokines and growth factors, e.g. IL1, IL5, IL6, LIF, OSM, IFNs, 
EGF, FGF, and PDGF. Moreover, it plays an important role in many different tissues and 
cellular functions. Many important and striking functions will be described in this section. 
1.3.2.1 Immune system 
The functions that STAT3 has in the immune system are very two-faced, where it can 
facilitate both pro- and anti-inflammatory functions. It pro-inflammatory functions are 
primarily depicted by the maturation of different immune cells. For example, STAT3 is 
essential for pro-B-cell development and IgG production in maturated B-cells 70. STAT3 gain 
of function mutations can cause autoimmunity conditions, with broad infectious phenotypes 
encompassing hepatitis, arthritis, enteropathy, cytopenias and lymphocytic interstitial 
pneumonia 43. On the other hand, genetic missense and in-frame deletions in the DNA 
binding domain or SH2 domain causing dominant negative forms of STAT3 can cause 
Hyper-IgE syndrome 71,72. The observed immunodeficiencies of patients include different 
abscesses, eczema, chronic mucocutaneous candidiasis, fungal infections, mucocutaneous 
and gastrointestinal infecions caused by different pathogens, as well as meningitis among 
others 43.  
Several studies have suggested that STAT3 mediates immunosuppression in the tumor 
microenvironment. STAT3 drives immunosuppression by upregulation of several anti-
inflammatory genes, e.g. IL6, IL10, VEGF and TGFβ, but also the downregulation of pro-
inflammatory genes, e.g. IFN-β, IFN-γ, IL12, TNF, CD80, CD86, and CXCL10 among 
others 24,28,70,73. Constitutive activation of STAT3 in different immune cells affects their 
ability to maturate. In dendritic cells this affects their antigen presentation function, whereby 
cytotoxic T-cell responses are affected 70. Thereby, more T regulatory cells are present in the 
tumor microenvironment promoting tumor growth. In addition, studies in mice have shown 
that STAT3 KO in NK cells and neutrophils leads to increased anti-tumor cytotoxic 
responses, in particular when cells detect specific tumor-derived factors 74. This indicates that 
STAT3 can act as a brake in different immune cells, regulating their anti-tumor response. 
STAT3 is also a main player in immune response evasion by tumor cells by effectively 
regulating PD-L1 and PD-1 expression on tumor and different immune cells 75–79. Moreover, 
it has been suggested that STAT3 is also activated in melanoma patients that do not respond 
to nivolumab, PD-1 antibody treatment, where the induced immune response is suppressed 
by increased STAT3 phosphorylation that drives IL10 expression, which increases regulatory 
T-cell percentages 80. Thus, STAT3 is involved in the formation of an immunosuppressed 
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tumor microenvironment, it can affect the cytotoxicity of immune cells, and contributes 
greatly to tumor cell immune evasion.   
1.3.2.2 Embryonic development 
The importance of STAT3 in embryonic development became apparent very early on. Gene 
targeting in mice revealed that the genetic knockout of STAT3 is embryonically lethal, while 
genetic knockout of any other STAT gene leads to either impaired responsiveness to 
interferons, specific interleukins or growth hormones 30,69. STAT3 is essential during 
embryogenesis because of its regulation of stem cells 81. The propagation of undifferentiated 
pluripotent embryonic stem cells is dependent on LIF 82. Expression of dominant negative 
STAT3 forms in embryonic stem cells promotes differentiation 83. Moreover, regulated 
STAT3 gene copy reduction results in the loss of STAT3 activity and potency of stem cells to 
self-renew 83. 
1.3.2.3 Cardiovascular system 
Physiological levels of ROS production together with cytokine signaling activates the 
JAK/STAT3 pathway, while elevated ROS production due to cellular stresses inhibits the 
STAT3 pathway 39,84–86. This is very important during myocardium remodeling upon 
exposure to different stressors, like exercise, infections and infarctions. STAT3 is a key 
regulator of angiogenic factors. Target gene VEGF-A promotes vascularization and vascular 
permeability, while Bcl-XL and MnSOD promotes survival of cardiomyocytes 87,88. Upon 
myocardial ischemia, STAT3 is activated and plays a cytoprotective role 89. During ischemia 
several different cytokines are released from myocardial cells, the cytokines activate the 
STAT3 pathway in cardiac progenitor cells inducing their differentiation into endothelial 
cells. Furthermore, progenitor cell differentiation is reduced in STAT3 knockout mice 90.  
The cellular communication between myocytes and fibroblasts is tightly regulated by STAT3.  
STAT3 knockout mice additionally develop severe cardiac fibrosis, which affects cardiac 
function, heart failure symptoms and increases mortality 91. Loss of STAT3 in cardiac 
fibroblasts enhances their proliferation, whereby cardiomyocytes can induce fibroblast 
proliferation 91. This indicates that STAT3 is essential for impeding cardiac fibrosis, which 
was further confirmed in STAT3 knockout mice showing a reduction in myocardial capillary 
density, while interstitial fibrosis was increased causing cardiomyopathy, impaired cardiac 
function and increased mortality 90. Thereby, STAT3 appears to play a complex part in the 
regulation and function of different cardiac cells upon cardiac stress.  
1.3.2.4 Mammary gland involution 
The role STAT3 has in mammary gland involution is one of the most striking, because it is 
the only biological process where STAT3 activation promotes cell death 92. Upon the loss of 
a suckling stimulus and consequential milk stasis, STAT3 becomes phosphorylated due to 
high levels of LIF expression 93. This induces mammary gland involution, which is the 
process of regression of mammary glands after lactation ceases. Conditional deletion of 
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STAT3 in mammary epithelial cells significantly delays the initiation and progression of 
involution 94. The cell death of the epithelial cells is caspase-independent and therefore not 
apoptotic, but is rather induced through the activation of a lysosomal-mediated cell death 
program 93,95. STAT3 drives the formation of cellular lysosomal vacuoles. Also, STAT3 
activation stimulates the uptake milk fat globules by the epithelial cells, switching their 
function from secretion to uptake of the globules. The globules contain the hydrolysate oleic 
acid that induces lysosomal leakage eventually leading to cell death 93. 
1.3.2.5 Mitochondrial STAT3 
The most extensively explored non-transcriptional function of STAT3 is its role in 
mitochondria. Mitochondria regulate cellular metabolism, cellular calcium gradients, and also 
produce reactive oxygen species through energy metabolism 96. The initial study that 
identified that STAT3 also resides in mitochondria, demonstrated mitoSTAT3 is serine 727 
phosphorylated and STAT3 KO affects function of electron transport chain complex I and II 
as well as decreases mitochondrial O2 consumption rates 34. Interestingly, the MEK-ERK 
pathway is essential for serine 727 phosphorylation of mitoSTAT3 97. MitoSTAT3 is 
oncogenic without assistance from STAT3 transcriptional activity, since Ras-dependent 
transformation requires serine 727 but not tyrosine 705 phosphorylation 33. Moreover, Ras 
induces serine 727 phosphorylation on STAT3, which increases mitochondrial respiration 
and facilitates Ras-dependent oncogenic transformation. MitoSTAT3 thus plays an important 
role in sustaining the metabolism needs during oncogenic transformation, which may sustain 
oxidative phosphorylation and decreased ROS accumulation in cancer cells. Thereby, it 
potentially could provide enough energy to sustain cell proliferation and tumor growth. 
1.3.2.6 STAT3 in cancer 
Constitutively activated STAT3 has been found in prostate, pancreatic, ovarian and brain 
tumors, as well as in breast carcinoma, head and neck carcinoma, melanoma, leukemia and 
lymphoma 38,98. Experiments performed with STAT3C, a STAT3 construct that is 
constitutively in an active dimer formation through intermolecular cysteine-cysteine bonds, 
led to the description of STAT3 as an oncogene 21. Implantation of normal mouse fibroblasts 
expressing STAT3C into nude mice leads to the formation of tumors. In addition, STAT3C 
expression in different cell types leads to the upregulation of oncogenic and angiogenic 
factors, driving oncogenesis and progression 26. STAT3 drives the transcription of multiple 
genes that are critically important to oncogenic transformation and the maintenance of the 
hallmarks of cancer (Figure 3; 2,28,99).  
STAT3 affects cell cycle progression through its regulation of genes like Cyclin-D1 and c-
Myc 28. It also contributes to cell survival through the upregulation of anti-apoptotic proteins 
of the Bcl-2 family and Survivin. Furthermore, it can also act as a repressor of the P53 gene 
by binding to its promoter, effectively preventing apoptosis 28. STAT3 in addition induces 
angiogenesis by facilitation of the expression of VEGF-A and b-FGF. Furthermore, STAT3 
drives the expression of metalloproteinases (MMPs), which promote tumor invasion by the 
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degradation of the extracellular matrix 28. It also drives tumor metastasis by upregulating 
several proteins, e.g. Vimentin, Snail, Twist and N-cadherin 99. The constitutive activation of 
STAT3 has also been described as a mechanism of chemotherapy and radiation therapy 
resistance in different preclinical tumor models, as well as patients. A positive feedback loop 
driving STAT3 activation is found in multiple drug-treated, oncogene-driven cancer cells. It 
is activated in melanomas that have become resistant to Vemurafenib, EGFR-driven lung 
cancer cells that are resistant to Erlotinib, Her2-driven cells resistant to Lapatinib and 
Trastuzumab, ALK-driven cells resistant to the ALK inhibitor TAE684 and Met-driven 
cancer cells resistant to Crizotinib 100–102. STAT3 activation also occurs upon resistance to 
different TKI inhibitors in myeloproliferative neoplasms (MPNs), e.g. different JAK 2 
inhibitors, BEZ235 a dual inhibitor of PI3K/AKT and mTOR signaling 103,104. Lastly, 
inhibition of STAT3 function leads to synthetic lethality in Imatinib-resistant BCR-ABL1-
positive CML cells 105. 
 
Figure 3. STAT3 functions and target genes delineated by cancer hallmark. The wide 
range of STAT3 functions and target genes can affect all hallmarks of cancer 2,28,99. 
 
1.3.3 STAT5a & STAT5b 
Even though STAT5a and b are encoded by different genes, their sequences minutely differ 
in their C-terminus, where STAT5a has 20 and STAT5b has 8 unique amino acids 106. Both 
drive gene transcription through binding to gamma-activated sequence (GAS) elements 106. 
While many studies have shown that different STATs can form dimers without necessity of 
phosphorylation 82,101,107,108. It remains unclear how dimerization of unphosphorylated STATs 
is regulated. The only unphosphorylated dimerized STAT crystal structure that was resolved 
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was of STAT5a This revealed that both monomers do not interact by SH2 domains, but rather 
interact by their coiled-coil and DNA-binding domains in an antiparallel conformation 109.  
STAT5 plays an important role in mammary gland and hematopoietic lineage differentiation 
38,50. Therefore, aberrant STAT5 activity is mostly found in breast and hematopoietic 
malignancies 110–113. Often, constitutive activation of STAT5 is regulated through upstream 
kinases mutations. In chronic CML STAT5 is activated through the BCR-ABL kinase, a 
specific mutation that drives oncogenic transformation of cells in many CML patients 114,115. 
In acute myeloid leukemia (AML) FMS-like tyrosine kinase 3 (FLT3) drives STAT5 
activation 116. And in MPNs the JAK2 point mutation V617F activates STAT5 117. In cancer 
STAT5 regulates expression of genes stimulating tumor cell survival, proliferation and the 
apoptosis resistance.  
 
1.4 REACTIVE OXYGEN SPECIES 
The utilization of the aerobic environment by living organisms permitted the evolution of 
many different complex species. The only more complex organisms that are anaerobic are 
several Loricifera, found at the bottom of the Mediterranean Sea 118. The oxygen metabolism 
by organisms therefore facilitated the development of complex life, however it has some 
inherent drawbacks. The metabolism of oxygen by cells can lead to the production of free 
radicals and ROS 96,119,120. Free radicals are molecules that contain one or more unpaired 
electrons 119.  
Endogenous ROS are mainly created in the mitochondria. They are an abundant side product 
from ATP production through oxidative phosphorylation (OXPHOS) by the electron 
transport chain 120,121. Inefficiency of the final step of OXPHOS where O2 is usually directly 
reduced to H2O, a small portion gets successively reduced, forming superoxide anions (O2.-), 
hydrogen peroxide (H2O2), hydroxyl radicals (OH.) and hydroxyl anions (OH-), eventually 
forming H2O (Figure 4). Other cellular organelles that utilize and consume oxygen are the 
endoplasmic reticulum (ER) and Peroxisomes. In order to facilitate proper protein folding the 
ER is kept in a constant state of oxidation 122. Through the activity of specific enzymes 
oxygen is used to oxidize cysteine residues on proteins to induce cysteine-cysteine bonding, 
in due process H2O2 is produced. Peroxisomes induce the β-oxidation of fatty acids, the most 
prevalent form of ROS is H2O2 123. 
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Figure 4. A simplified scheme of oxygen reduction into water. In the final step of 
OXPHOS a small portion of O2 gets successively reduced, forming superoxide anions (O2.-), 
hydrogen peroxide (H2O2), hydroxyl radicals (OH.) and hydroxyl anions (OH-), eventually 
forming H2O 
 
Balancing ROS is important for cell survival and cellular signaling. In normal cells ROS 
production is counterbalanced by antioxidant scavenging systems, creating redox 
homeostasis. There are different types of ROS species, in the form of ionic, free radical and 
non-radical species, which are synthesized as by-products of oxygen metabolism. In redox 
homeostasis these species play an important role in cellular signaling. It is well described that 
different cytokines and growth factors induce cellular ROS, which is essential to induce 
downstream target phosphorylation 124–127. This mechanism involves NADPH oxidases (Nox) 
and negative regulators of phosphorylation, the protein tyrosine phosphatases (PTPs) 
124,128,129. Many PTPs, like PTP1B, are sensitive to increases to ROS, and become inactivated 
due to protein oxidation, which facilitates subsequent phosphorylation of cytokine and 
growth factor receptors and downstream kinases 130. 
Different oncogenes can induce ROS in transformed cells, which is even required for the 
tumorigenicity of the oncogene in specific instances 12. In combination with the ability of 
proto-oncogenes, including RAS, to induce antioxidant expression to counteract the higher 
ROS levels suggests that cancer cells have increased rates of ROS generation and 
elimination, as well as aberrant regulation of redox homeostasis 131. Moreover, this may make 
cancer cells more susceptible to abrupt alterations in redox balance and lead to selective cell 
death 12,132. Therefore therapeutics inducing ROS production, as well as its metabolism is 
widely and intensively explored in research (Figure 5) 12,132.  
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Figure 5. Targeting ROS generation and elimination as anticancer strategy. Normal cells 
have low basal levels of ROS and therefore also their antioxidant systems are utilized at low 
levels. Due to increased cellular metabolism and the tumor microenvironment, cancer cells 
have higher levels cellular ROS and their antioxidant systems are more engaged in 
scavenging to prevent cell death. Cancer therapeutics can induce higher ROS levels affect 
normal cells, however the cellular antioxidant systems are capable of scavenging the 
additional ROS. If ROS levels become too high cancer cells are unable to further engage their 
antioxidant systems, which causes increased cellular stress and inevitable cell death 12. 
 
1.5 REDOX & ANTIOXIDANT PATHWAYS 
There are two major pathways that control cellular redox signaling and antioxidants. Both 
pathways are intertwined in a wide range of cellular processes, e.g. proliferation, antioxidant 
activity, kinase pathway signaling and redox homeostasis 133–135. The pathways are named 
after predominant components, namely the glutathione (GSH) and the thioredoxin (Trx) 
pathways 133–135. Both pathways have mechanisms and functions that are distinct as well as 
complementary. Notably, functions of both pathways have been intricately linked to 
oncogenesis, cell proliferation and tumor progression 12. Both systems and their function in 
cancer will be described below. 
1.5.1 Glutathione pathway 
The GSH pathway is composed of glutathione, glutathione peroxidase (GPx), glutaredoxin 
(Grx) and glutathione reductase (GR) 134. GSH is a small tripeptide, consisting of glutamate, 
cysteine and glycine. It is synthesized by two different synthetases, first glutamate and 
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cysteine form γ-glutamylcysteine via glutamate cysteine ligase, and second glycine is added 
forming GSH via GSH synthetase 136,137. It is a highly abundant intracellular peptide, with a 
range between 1 and 10 mM in mammalian cells 137. In its reduced state GSH is a single 
tripeptide, while oxidized (GSSG) it forms a pair through a disulfide bond of two cysteine 
thiols. GSSG can be reduced again by GR through consumption of Nicotinamide adenine 
dinucleotide phosphate (NADPH) 134. The process of S-glutathionylation is important for 
protecting protein thiols from irreversible oxidation when oxidative stress levels are 
increased. When the GSH/GSSG ratio is disrupted GSH forms disulfide bonds with reactive 
thiols, in order to prevent irreversible thiol oxidation of proteins 138. Apart from the 
importance of GSH for cellular protection against different stressors, GSH is also an 
important signaling peptide 139. 
1.5.1.1 Glutathione Peroxidase 
GPxs are peroxidases that catalyze the removal of hydrogenperoxide and other 
hydroperoxides from cells by utilization of GSH 139. Dependent on the peroxide this catalysis 
leads to the generation of H2O or alcohols 140. The human genome encodes eight different 
GPx genes, of which five (GPx1-4 and GPx6) contain a rare selenocysteine (Sec) in their 
active site, while other isoforms contain a cysteine 141. Substitution of Sec to cysteine leads to 
drop in activity in a magnitude of two to three orders 142. Sec-containing GPxs have a very 
high rate, 105-108 M-1s-1, of reaction with H2O2 143. GPx4 is unique in that it is the only 
isoform that also directly reduces lipid peroxides, e.g. phospholipids, cholesterol and fatty 
acids 144–146. When GPx4 is inhibited the peroxidation of polyunsaturated fatty acids can drive 
ferroptosis, a regulated nonapoptotic form of cell death 146. 
1.5.1.2 Glutaredoxin 
Humans express four different Grx family members 134. They can be subdivided by their 
active site motif, where Grx1 and Grx2 contain a dithiol CXXC active site motif, while Grx3 
and Grx5 contain a monothiol CXXS active site motif 134. Grx1 and Grx3 are mostly found in 
the cytosol, while Grx2 and Grx5 mainly reside in the mitochondria where they exert 
different redox-related functions. Grxs mainly are oxidized by different cellular substrates, 
e.g. Ribonucleotide reductase (RNR), apoptosis signal-regulating kinase (ASK1), and are 
reduced by GSH in a two-step reaction 134. In addition to their main functions, Grxs were also 
found reduce Trx1 and peroxiredoxins (Prxs), which is a good illustration of mechanical 
complementation between both cellular antioxidant pathways 147,148.  
1.5.2 Thioredoxin pathway 
The Trx pathway is composed of Prx, Trx and Thioredoxin Reductase 1 (TrxR1) 133. Because 
of the focus of the thesis, TrxR1 will be discussed separately after this section.  
1.5.2.1 Peroxiredoxin 
Analogous to the GPxs in the GSH pathway, Prxs are the main thiol peroxidases for the Trx 
pathway 133. They have a similar reactivity rate with H2O2 compared to Gpxs 143,149. The Prx 
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family contains six different members Prx1-6 135,150. Also here some members, Prx1-4, have a 
dithiol active site motif, which upon thiol oxidation form a dimer through intermolecular 
disulfide bonding 135. Prx5 also contains a dithiol active site, however in contrast with Prx1-4 
it forms an intramolecular disfulde bond, thereby remaining monomeric when oxidized. Prx6 
is the only monothiol Prx, and is another crossover between both antioxidant pathways 
because it utilizes GSH instead of Trx as its reductant 151. Prx1 and Prx2 are mainly located in 
the cytosol and appear to have some redundant functions 151. Prx3 resides in the 
mitochondria, while Prx4 is found in the ER 151. Prx5 has been detected in the cytosol, 
mitochondria and peroxisomes 151. The function of Prxs in cells that are exposed to H2O2 is 
under debate. Different studies from primarily the lab of Tobias Dick claim that different Prxs 
can form redox relays together with the other players of the Trx pathway 149,150. Where Prx 
can relay oxidative equivalents directly to Trx or other substrate proteins, amongst which is 
STAT3 (Figure 6) 149. Knockdown or knockout of Prx2 or both Prx1 and Prx2 prevents the 
oxidation of these redox-regulated proteins upon H2O2 exposure 150. A shortlist of Prx1 and 
Prx2 substrate proteins are mentioned in the Thioredoxin subsection below. 
 
Figure 6. Kinetic model of Prx-mediated redox relay involving STAT3. H2O2 oxidizes a 
cysteine in the Prx2 active site, causing Prx2 dimerization. Oxidized equivalents are relayed 
to either reduced STAT3 and subsequently passed to Trx1, or directly to Trx1, which is kept 
in reduced form by TrxR1 enzymatic activity driven by NADPH consumption 152. 
 
1.5.2.2 Thioredoxins 
Trx is the pivotal enzyme of the Trx pathway. The three different Trx proteins all have the 
same disulfide motif in their active site, Cys-Gly-Pro-Cys. Trx1 resides in the cytosol, 
nucleus and is even found extracellularly, Trx2 is located in the mitochondria and SpTrx is 
only found in spermatozoa 135,153. Trxs mainly keep Prxs and other substrate proteins reduced, 
and Trx is consequently reduced mainly by TrxR 133,154. However, another functional 
crossover between the two pathways is that Grx2 can also reduce Trx1 155. A group of 
different cellular proteins that are substrates of Trx, besides Prxs, are amongst others: 
STAT3, p53, RNR, ASK1, phosphatase and tensin homolog (PTEN), annexin A2 (ANXA2), 
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cystathione β-synthase (CBS) and PTPs 149,150,156–158. The reduction of these substrates 
determines the activity and function of these substrates. Trx is therefore a very important 
enzyme for a wide scale of cellular processes. 
 
1.6 THIOREDOXIN REDUCTASE 1 
TrxRs consist of only three family members, cytosolic TrxR1, mitochondrial TrxR2 and testis 
specific thioredoxin glutathione reductase (TGR) 154. They are a family of pyridine 
nucleotide-disulphide oxireductases with a redox catalytic site similar to that of GRs 154. 
However, TrxRs also contain a unique amino acid, a Sec residue is situated at the penultimate 
position of the protein amino acid chain 159. In its oxidized state, the selenolate of Sec is three 
orders in magnitude more reactive with electrophilic moieties than the thiolate of a cysteine 
160. TrxR consumes NADPH to reduce Trx, and therefore is the catalyst of the Trx pathway 
154. Knockout of either TrxR1 or TrxR2 is embryonically lethal in mice. As catalyst, cytosolic 
TrxR1 therefore regulates different cellular processes, e.g. activation of signaling pathways 
and antioxidant activities. In addition, TrxR1 is targeted by a plethora of anticancer drugs and 
TrxR1 inhibition was shown to contribute to their therapeutic effects 159,161. Thus, TrxR1 has 
been proposed as a good therapeutic target for cancer treatment. The function, selenoprotein 
synthesis machinery, substrates, small molecule inhibitors, as well as its function in cancer 
will be discussed in this section. 
1.6.1 Structure and activity 
TrxR1 has a size of approximately 55 kilodalton (kDa) and usually resides as a homodimer 
through a covalent bond of two oxidized tryptophan residues (Trp114) that are solvent 
exposed on the protein surface 162. Upon oxidation it can relay electrons with the flavin 
adenine dinucleotide (FAD) moiety of TrxR1. The oxidation state of Trp114 determines the 
ability of TrxR1 to form dimers, and even facilitates tetramer and higher oligomer formation 
162. In order to reduce Trx, TrxR1 reduces itself by transferring electrons from the FAD-
containing cysteine dithiol active site of one subunit to the Sec-containing active site of the 
other subunit 163. The FAD moiety trasnfers electrons from NADPH upon its binding. The 
electrons are then transferred from the FAD to the cysteine dithiol of the same active site and 
subunit 163. This reduced dithiol motif is then able to reduce the selenothiol motif on the other 
subunit of the dimer, which then is able to reduce oxidized Trx or other substrates 162,163. 
In its function the Sec amino acid is the same as that of cysteine, the only difference is the 
substitution of a selenium atom for that of a sulfur atom, which even posses an equal amount 
of valence electrons 164. Sec is highly reactive however, significantly more than cysteine, their 
respective dissociation constants are pKa = 5.5 and pKa = 8.5 159. The natural presence of 
selenium is however much lower than sulfur, and only 25 human proteins are encoded to 
contain a Sec residue 165. 
 24 
1.6.2 Substrates 
TrxR1 has a wide range of different substrates, of which the most prominent is Trx1. Other 
proteins that are reduced by TrxR1 include thioredoxin related protein 14kDa (Trp14), Grx2, 
protein disulfide-isomerase (PDI) 124,135. It is interesting that the list of TrxR1 substrates not 
only encompasses cellular substrates. There are multiple cellular molecule substrates, e.g. 
cytochrome C, selenite, selenocysteine, menadione and H2O2, but also substrates not found in 
cells, e.g. 5,5′-dithiobis-(2-nitrobenzoic  acid) (DTNB) and 5-hydroxy-1,4-naphthalenedione 
(Juglone) 154,166. The different cellular functions of the known substrates of TrxR1 effectively 
link its function to different processes including proliferation, apoptosis, regulating redox 
homeostasis and protein folding 161.  
1.6.3 TrxR1 in cancer 
Due to the variety of different substrates described above TrxR1 facilitates oncogenesis, 
proliferation, angiogenesis, apoptosis resistance, metastasis, and supports tumor cells further 
by driving the antioxidant response needed for cancer cell survival due to higher levels of 
ROS created by the tumor microenvironment and increased cellular metabolism 12,167. 
Metabolism in cancer cells is moreover often erroneous leading to additional ROS synthesis 
12. In addition to its direct involvement as an antioxidant enzyme, TrxR1 has been linked to 
many different oncogenic processes indirectly. TrxR1 protein expression is upregulated in 
different tumors, including breast cancer where tumor tissue expresses significantly higher 
levels of Trx1 and TrxR1 compared to healthy breast tissue of the same patients and Trx1 and 
TrxR1 were both correlated with poor overall survival, disease free survival and distant 
metastasis free survival 168. It is further upregulated in malignant melanoma, colon cancer, 
non-small cell lung cancer, thyroid cancer and oral squamous cell carcinoma 169–173. 
Moreover, TrxR1 expression levels between cancer patients have been positively correlated 
to a worse overall prognosis and overall survival 174,175. 
TrxR1 facilitates cellular proliferation through the reduction of RNR by the Trx pathway. 
RNR reduces ribonucleotides into deoxyribonucleotides, the building blocks of DNA 124. It 
was shown that RNR activity is decreased upon inhibition of TrxR1 176. ASK1 is a well-
described substrate of Trx1 and is kept in a reduced state to prevent its autophosphorylation 
177. It is a MAPK family member that when activated it induces apoptosis through activation 
of p38 and JNK 177. Overexpression of Trx1 under hypoxic conditions increases HIF-1 levels, 
an important oxygen sensing transcription factor induced during hypoxia, and leads to higher 
levels of VEGF stimulating angiogenesis 178. Furthermore, Trx1 in breast cancer cells leads to 
a more invasive phenotype. While Trx1 knockdown decreased invasiveness and cellular 
migration, the mechanism of invasion and migration might involve the upregulation of MMP-
9 168,179. 
1.6.4 Targeting TrxR1 
Targeting of either the Trx or GSH pathway is considered an interesting therapeutic avenue 
for anticancer treatment, since normal cells only require one of the two pathways to be 
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functional for survival 180,181. Therefore, simultaneous disruption of both pathways could lead 
to adverse side effects. Many pan-TrxR inhibitors have been described and two are approved 
for clinical use, Auranofin for rheumatoid arthritis and arsenic trioxide for treatment of acute 
promyelocytic leukemia (APML) 182–184. Auranofin is a gold-containing compound, which 
causes mild adverse toxicities in humans. Different clinical trials are being conducted to 
assess the efficacy of Auranofin as monotherapy for ovarian cancer, fallopian tube cancer, 
and chronic lymphocytic leukemia (CLL) 185,186. Gold is a transition metal, due to their 
electrophilic nature many transition metal containing compounds have been shown to be 
potent inhibitors of TrxR1 187. One platinum-containing compound, Cisplatin, is a widely 
used chemotherapeutic that alkylates purine bases on DNA, thereby preventing DNA repair 
mechanisms and causing replicative stress 188. Interestingly, Cisplatin was also shown to 
target TrxR1, and Cisplatin-resistant cells were shown to upregulate Trx1 and TrxR1 
expression 189,190. Furthermore, Curcumin, a plant-derived polyphenol, is another inhibitor of 
TrxR1 that irreversibly binds to the Sec and cysteine residues in the TrxR1 active site 191. It 
and its many derivatives are well known for its anticancer and antiangiogenic effects 192,193. In 
addition, it was shown in multiple studies that both the STAT3 as well as nuclear factor-
kappaB (NF-κB) pathways are inhibited by Curcumin 192,194,195. 
There are multiple efficacious inhibitors of TrxR1, however none do not affect mitochondrial 
function indicating simultaneous targeting of TrxR2 196. Consequently, one recent study 
published by the Arnér lab performed a high throughput screening campaign to identify 
specific small molecule inhibitors of TrxR1 that did not affect TrxR2 function 197. The study 
focused on the in vitro, cellular and in vivo effects of patented compounds TRi-1 and TRi-2, 
while a third patented compound was also identified TRi-3, it was omitted from the final 
published work. TRi-3 is mentioned here because of its structural similarity to the compounds 
identified in Paper III of this thesis. TRi-1 and TRi-2 were shown potently inhibit TrxR1 
function, have minimal effect on mitochondrial function 197. Both were cytotoxic to cancer 
cells, in comparison normal cells were relatively unaffected. Both compounds showed 
minimal toxicity in mice and showed good efficacy in several in vivo mouse tumor models. 
1.6.5 SecTRAPs 
In addition to inhibition of TrxR1 enzymatic activity it was shown that specific electrophilic 
small molecule inhibitors of TrxR1 more selectively bind to the Sec-residue in its C-terminal 
active site, leading to the formation of selenium compromised thioredoxin reductase-derived 
apoptotic proteins (SecTRAPs) 198. The inhibition of the Sec-containing active site prevents 
TrxR1 from reducing Trx1. However, the secondary active site, containing a FAD moiety 
and a redox active disulfide/dithiol motif), still has NADPH oxidase activity and remains able 
to redox cycle with substrates such as Juglone and other Quinones (Figure 7) 199. A cellular 
SecTRAP substrate has however not been identified so far 198. The NADPH oxidase activity 
combined with the lack of its normal redox-dependent antioxidant activity, should transform 
the SecTRAPs into a gain of function pro-oxidant protein 198. This gain of function could 
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results in increased ROS production, thereby making TrxR1 a target for anticancer 
therapeutics with a unique additive effect to enhance apoptotic cell death.   
 
 
Figure 7. TrxR1 redox activity and SecTRAPs. A. The first active site of TrxR1 contains a 
FAD moiety that utilizes electrons from NADPH, which flow to the N-terminal disulfide of 
the same active site. Since TrxR1 resides in the cytosol as a dimer, the electrons can then be 
transferred to the C-terminal active site containing a selenosulfide. The reduced C-terminal 
active site can reduce Trx1 or other cellular substrates. B. Occupation of the Sec residue of 
the C-terminal active site by an electrophilic small molecule inhibitor leads to inactivation of 
that active site. Therefore, TrxR1 can no longer reduce Trx1. The N-terminal active site 
however remains active, which results in an activity similar to NADPH-oxidase and can 
actively redox-cycle with quinones generating superoxide 198,199. 
 
1.7 REDOX REGULATED TRANSCRIPTION FACTORS 
Different transcription factors contain specific residues that can be modified post-
translationally, including phosphorylation, acetylation, and oxidation/reduction. Due to 
changes in the cellular redox balance, specific cysteine residues become either oxidized or 
reduced which determines the activity of these transcription factor. Here the redox regulation 
of the transcription factor systems Nrf2-Keap1, the NF-κB and STAT3 will be described. 
1.7.1 Nrf2-Keap1 
Several transcription factors have been described to be subject of redox regulation. The most 
well described and explored transcription factor is NF-E2 related factor 2 (Nrf2), which upon 
activation drives transcription of many cytoprotective genes and is one of the main regulators 
of the cellular oxidative stress response 200,201. Under normal conditions Nrf2 resides in the 
cytoplasm in a complex with Kelch-like ECH associated protein 1 (Keap1), a ubiquitin E3 
ligase which continuously targets Nrf2 for proteasomal degradation 202. When cells are 
exposed to oxidative stresses or electrophilic attacks specific cysteine residues on Keap1 
become oxidized disrupting the Nrf2-Keap1 complex 203. Consequently, Nrf2 is stabilized 
and cellular levels rapidly increase. Nrf2 then translocates to the nucleus and induces 
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transcription of genes involved in cellular protection against oxidative and xenobiotic stresses 
204. These genes contain specific binding elements in their promoters, known as antioxidant 
response elements (ARE) or electrophilic response elements (EpRE) 204,205. In cancer, somatic 
mutation in both NRF2 and KEAP1 genes often occur, which leads to constitutive activation 
of Nrf2 203. This facilitates tumor therapy resistance and driving disease progression 203.  
1.7.2 NF-κB 
The NF-κB pathway has been showed to play a central role in both immunity and cancer 
development. NF-κB consists of a heterodimer of p65 and p50, which are sequestered in the 
cytoplasm by IκB, regarded as the main gatekeeper of NF-κB activation 206. Upon 
extracellular stimulation by inflammatory cytokines, e.g. TNF-α, IL-1 and 
Lipopolysaccharide (LPS), IκB is phosphorylated and targeted for proteasomal degradation 
207. Hereby, NF-κB gets released and translocates to the nucleus where it drives transcription 
of a plethora of genes, which regulate proinflammatory mediators, i.e. iNOS, COX-2, TNF-α, 
IL-1 and IL-8 208. Other target gene products promote cancer progression by inhibition of cell 
death, promotion of cell proliferation, and facilitation of epithelial-mesenchymal transition 
(EMT) 209. Under oxidative stress NF-κB activation is impeded. Interestingly, the Trx system 
affects NF-κB in multiple ways. Trx overexpression was shown to stabilize IκB, while Trx 
can also reduce oxidized cysteine residues on nuclear NF-κB facilitating DNA binding 
affinity 210,211. An additional inhibitory protein of NF-κB was found, which has to be 
dissociated from the cytosolic NF-κB complex in order to facilitate pathway activation. 
Dynein light chain LC8, a redox-sensitive interacting protein of IκB, contains a cysteine 
residue that in unstimulated conditions is reduced 212. Two LC8 proteins reside in the cytosol 
together with IκB preventing NF-κB activation. However, upon binding of TNF-α, IL-1, or 
LPS to the TNF receptor 1 (TNFR1), NADPH oxidases (Nox) are activated and start the 
generation of intracellular ROS 213. The ROS oxidizes the cysteines on LC8, inducing the 
formation of an LC8 homodimer, which dissociates from IκB 214. In order to restore its 
inhibitory contribution the disulfide bond is reduced Trp14, which is subsequently reduced by 
TrxR1 214.  
1.7.3 STAT3 
Both JAK and STAT3 phosphorylation can be regulated by alterations in redox homeostasis. 
H2O2 can increase JAK2 phosphorylation, due to activation of the tyrosine-protein kinase Fyn 
and perhaps in addition inhibition of redox sensitive PTPs 215. Moreover, exposure of 
unstimulated cells to H2O2 can induce STAT3 activation through activation of both JAK2 and 
TYK2 84. These observations also involve the activity of Nox 216. Also, it appears that in 
starved cells, ROS can activate JAK-STAT3 pathway leading to the increased expression of 
IL6, which might indicate the formation of an autocrine feed forward loop 217. This loop 
could maintain STAT3 activity and possibly promote cancer cell survival.  
In contrast, reports have also been made that ROS can inhibit JAK-STAT pathway activation 
149,218,219. This might be explained through a discrepancy in experimental setup, whereby 
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cytokines can no longer activate the signaling pathway due to direct oxidation of JAK and 
STAT proteins. In this respect, a potential mechanism of STAT3 inhibition is due to 
glutathionylation of specific cysteine residues, which impeded STAT3 phosphorylation, 
nuclear translocation and transcriptional activity 220,221. The glutathionylation could be 
reversed by the addition of Grx1, however Grx1 overexpression did not significantly affect 
nuclear translocation or transcriptional activity of STAT3 by cytokine stimulation 220. 
Moreover, cysteine residues in the JAK2 catalytic domain have been shown to be redox 
sensitive and can become oxidized, affecting kinase activity 222. Similarly, STAT3 was 
shown to form dimers and oligomers by oxidization of specific cysteine thiols 149. It was 
suggested that this oxidation is due to a peroxidase-based redox relay. H2O2 readily oxidizes 
active site cysteines on Prx2, which can transfer their oxidizing equivalents to several redox-
regulated proteins. STAT3 was identified as one of the target proteins of Prx2 149. Moreover, 
cytokine stimulation was also able to induce Prx2 and STAT3 oxidation, and Prx2 
knockdown led to an increased transcriptional activity of a cytokine-stimulated STAT3 149. 
These contradictory findings might be explained by discrepancies in measurement time 
points, where initial ROS induction might directly oxidize STAT3 and inactivate it, while 
longer exposure to ROS possibly leads to antioxidant effects which cause subsequent the 
reduction of STAT3, permitting the activation of the pathway. Indeed, the formation of 
disulfide-linked STAT3-Trx1 intermediates was observed after H2O2 exposure, indicating the 
ability of the Trx system to increase the reduced pool of STAT3 protein (Figure 6) 149. 
Inhibition of the important cytosolic reductase in the Trx system, TrxR1, thereby also leads to 
inhibition of STAT3 activity 149. Not only do TrxR1 inhibitors induce Prx2 oxidation, they 
might also limit the subsequent Trx1-mediated reduction of STAT3.  
 
1.8 TARGETING STAT3 IN CANCER 
Constitutive activation of STAT3 has been detected in many different human cancers. In 
addition, tissue-specific induced knockout of STAT3 does not overtly affect normal tissues in 
vivo. These two observations have led to the belief that STAT3 inhibition could be a very 
lucrative avenue for targeted anti-cancer therapy, specifically targeting the tumor that 
depends on STAT3 activation, while other healthy tissues should remain unaffected. This has 
led to the development of many different strategies to target STAT3 signaling 24,223. Below, 
indirect targeting methods, as well as direct STAT3 targeting methods will be addressed. 
1.8.1 Indirect STAT3 targeting approaches 
Targeting the STAT3 signaling axis can be approached from targeting IL6, JAK, or STAT3. 
The first JAK targeted therapy that was approved by the FDA is Ruxolitinib 224,225. An orally 
bioavailable drug with selective JAK1 and JAK2 inhibition showed clinical efficacy in the 
treatment of polycythemia vera and MPNs224–227. Its use in MPNs is largely to alleviate 
splenomegaly and other disease-related symptoms 227,228. Tofacitinib is another orally 
administered drug with selective JAK1 and JAK3 inhibition, with lower JAK2 binding 
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affinity 229–231. It has been approved for clinical use in rheumatoid arthritis, and is currently 
being clinically evaluated for treatment of several other inflammatory conditions 24. 
Unfortunately, none of the JAK inhibitors have shown clinical antitumor efficacy 24. With 
ongoing clinical trials showing some clinical benefit of combination treatment strategies, 
JAK inhibitors could possibly be used as anticancer therapeutics in the future. 
Besides the other kinase targeting small molecules, many different and creative methods have 
been utilized to inhibit STAT3 in preclinical settings. Peptidomimetics derived from different 
origins targeting the STAT3 SH2 domains, despite having high affinity binding, did not 
affect STAT3 transcriptional activity in cells 232. This might be due to their poor stability and 
cellular permeability, effectively negating their effect in vivo 232. Another method is by 
effectively diverting phosphorylated STAT3 dimers by decoy oligonucleotides (ODN) 
containing the consensus STAT3 response element. Intratumoral injection of the ODN in 
head-and-neck cancer patients demonstrated efficacy through downregulation of STAT3 
target genes 233. Subsequently, a more stable cyclic form of ODNs was generated with 
improved ADME properties and no apparent toxicities at high doses 24. Lastly, AstraZeneca 
has substantially invested in the development of another method of STAT3 targeting 234–236. 
They are currently in early clinical trials with AZD9150, a second-generation antisense 
oligonucleotide targeting STAT3 mRNA 236. After promising preclinical findings, AZD9150 
demonstrated efficacy in patients with treatment-refractory lymphoma and non-small cell 
lung cancer 236,237. Although initial promising results, there are major challenges with further 
clinical implementations of ODNs and AZD9150. Their high molecular weight could mean 
that efficient delivery is quite challenging, especially in contrast to small molecule inhibitors. 
1.8.2 Direct small molecule inhibitors of STAT3  
Different small molecule inhibitors have gone through preclinical development over the years 
and several have been tested in a clinical setting as anti-cancer drugs. Most of the designed 
small molecules were developed with the rationale to bind to the STAT3 SH2 domain. 
Through occupation of the binding site of the phosphorylated transactivation domain, STAT3 
dimerization should effectively be impaired and transcriptional activity impeded 238,239. 
Unfortunately, none of the tested inhibitors have been approved for clinical use, due to lack 
of therapeutic response or treatment related toxicities 24,26. Some of the most widely used and 
most recently identified STAT3 small molecule inhibitors implemented in early clinical trials 
will be described. 
1.8.2.1 STA-21 
One of the first hits from a STAT3 SH2 domain virtual screening was STA-21 240. 
Approximately 429.000 small-molecule organic compounds were virtually screened. 100 out 
of the 200 best scoring small molecules were purchased and further evaluated. These 100 
compounds were screened in a cellular STAT3-dependent luciferase assay, where it inhibited 
STAT3-dependent but not -independent luciferase activity. It was then shown to inhibit 
STAT3 DNA binding, induce cell death in STAT3-dependent cell lines, affect nuclear 
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translocation and dimerization 240. A series of STA-21 derivatives have since been designed 
with more favorable pharmacokinetic properties. This LLL compound series was 
consequently patented and the compounds LLL-3 as well as LLL-12 were shown to inhibit 
STAT3 activity in different preclinical glioblastoma and leukemia models 241. 
1.8.2.2 Stattic 
In a fluorescence-based polarization assay of approximately 18.000 compounds, Stattic was 
identified 242. Since its discovery has widely been used as a STAT3 inhibitor in preclinical 
STAT3 biology studies. Unfortunately, it has more recently come to light that Stattic is an 
electrophilic compound, which covalently bind to nucleophilic amino acids, like reduced 
(seleno-)cysteine residues (Figure 8A) 243. The exact biological mechanism of STAT3 
signaling inhibition has however not been completely elucidated. The original study that 
identified Stattic as a STAT3 inhibitor, however designed a validation pipeline that has also 
widely been utilized to identify other STAT3 small molecule inhibitors. This pipeline consists 
of: an in silico or in vitro binding assay, cellular reporter assays, EMSA for DNA binding, 
nuclear translocation by immunofluorescence, phosphorylation of STAT3, STAT1 and other 
pathway kinases by western blotting, and differential cytotoxicity on STAT3-dependent and –
independent cell lines. Direct binding of the small molecule to STAT3 protein is shown in 
silico or in vitro, while STAT3 inhibition is measured through indirect methods of 
transcription factor activity in cells or in vivo. 
1.8.2.3 S3I-201 
In another STAT3 SH2 domain virtual screening campaign of approximately 150.000 small 
molecules, S3I-201 was found as a potent SH2 domain binder 244. A different docking 
approach was utilized, where the STAT3 phosphopeptide crystal structure was docked into 
the SH2 domain, and small molecules were scored for binding into the predicted 
phosphopeptide binding site. The in silico results were verified by inhibition of STAT3 DNA 
binding by EMSAs, STAT3-dependent luciferase reporter, STAT3-dependent cell line 
cytotoxicity, target gene downregulation, and STAT3-dependent xenograft studies. More 
recently it was indicated that S3I-201 is also an electrophilic compound, which reacts with 
GSH and unspecifically alkylates different proteins in cells (Figure 8B) 245.  
1.8.2.4 BP1-102 
Many compounds have been derived from the structural backbone of S3I-201. One 
compound, BP1-102, was designed to more potently bind to the same SH2 domain binding 
site 246. It bound with nanomolar affinity to STAT3. It had good activity in the STAT3 
fluorescence polarization assay. Moreover, it also inhibited STAT3 DNA binding and 
phosphorylation, while not affecting phosphorylation of other kinases in the STAT3 pathway. 
Interestingly, it had good PK/PD properties, and was orally bioavailable, inducing potent 
antitumor efficacy in tumor-bearing mice. This compound was later also found to contain an 
electrophilic moiety, which covalently binds to GSH (Figure 8C) 247. These properties were 
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deemed unfavorable and using medicinal chemistry another derivative was designed, which 
could be evaluated in further preclinical testing. 
1.8.2.5 OPB compound series 
Several different compounds from Otsuka pharmaceuticals have been tested in early clinical 
trial stages. Phase 1 clinical trials have been conducted with OPB-31121, OPB-51602 and 
OPB-111077, showing moderate efficacy in a subset of patients 248–254. Only sparse 
preclinical findings have been published on these compounds, the mechanism of action of 
OPB-51602 has been more elucidated than the other two compounds. However, the other two 
compounds are claimed to have similar anticancer activity. Initial studies implicated that 
targeting of the STAT3 SH2 domain leads to mitochondrial dysfunction due to interference 
of the mitochondrial STAT3 pool 255. In addition, OPB-51602 treatment leads to aggregation 
of STAT3 in autophagosomes, while also blocking late stage autophagy 255. In contrast, 
another study published that STAT3 knockdown failed to rescue cells from compound 
cytotoxicity and inhibition of mitochondrial function 256. Thereby showing that mitochondrial 
dysfunction is STAT3-independent, and that OPB-51602 is a potent and specific inhibitor of 
the mitochondrial complex 1. Through inhibition of oxidative phosphorylation, a widely 
observed mechanism of TKI resistance, cancer cells that are more dependent on the function 
electron transport chain are more sensitive to treatment with OPB-51602 256.  
Since many of the described STAT3 small molecule inhibitors were shown to not specifically 
target the STAT3 SH2 domain, the search for a potent and specific inhibitor of STAT3 
signaling is still active 243,245,247. Meanwhile, clinical trials for cancer treatment are also being 
conducted with FDA approved drugs that were found target STAT3 signaling indirectly. One 
example is Pyrimethamine, an anti-microbial used for treatment of toxoplasmosis and malaria 
257,258. It inhibits STAT3 activity at concentrations that are safe for patients. It is currently 
being tested in chronic and small lymphocytic leukemia 257,258. 
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Figure 8. Electrophilic STAT3 small molecule reactivity with nucleophiles. A-C. 
Proposed mechanism of interaction of Stattic (A), S3I-201 (B) and BP1-102 (C) with cysteine 
thiols, interaction can also occur with other nucleophilic residues.  
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2 DOCTORAL THESIS 
2.1 PURPOSE & AIMS 
Many small molecule inhibitors of STAT3 have been described in the scientific literature. 
Several of them have also been tested in early clinical trials, but failed to show clinical 
benefit. Therefore, the overall aim of this thesis was to elucidate the mechanism of action 
of known and novel small molecule inhibitors of STAT3, and in due process critically 
assess the methods used to identify direct targeting small molecule inhibitors of STAT3. 
The specific aims were as follows: 
• Elucidate the mechanism of action of classical and novel inhibitors of STAT3 
signaling. 
• Develop novel methods that can be utilized to identify novel small molecules that 
specifically target the STAT3 SH2 domain.  
• Develop novel methods that can be utilized to identify the cellular target of small 
molecule inhibitors of STAT3 signaling. 
These aims were addressed in the three papers of this thesis, where we attempted to answer 
the following specific questions: 
Paper I 
• Is it possible to perform a high-throughput cell-based screening method for STAT3 
inhibition? 
• Are there any potent novel compounds that inhibit STAT3 function, without affecting 
upstream kinase activity? 
Paper II 
• Can differential scanning fluorimetry be utilized as a method for the identification 
novel small molecule inhibitors of STAT3? 
• Do classical STAT3 small molecule inhibitors specifically target the STAT3 SH2 
domain? 
Paper III 
• Is it possible to synthesize very potent small molecule inhibitors of STAT3 signaling? 
• What is the cellular target of our identified electrophilic small molecule inhibitors? 
• Why are electrophilic small molecules identified as STAT3 inhibitors? 
• What is the mechanism of action of STAT3 transcriptional activity inhibition of 
electrophilic small molecules? 
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2.2 SCIENTIFIC METHODOLOGIES 
2.2.1 Cellular STAT3 luciferase reporter assay (Paper I & III) 
A reporter gene is a gene that can encode different identifiable characteristics, which often 
can be quantified. Commonly used reporter genes include fluorescent proteins, luciferases or 
other enzymes, like lacZ. The expression of the reporter gene is regulated by the activity of 
the gene of interest, by the introduction of a regulatory sequence in the promoter of the 
reporter. Thereby, activity of the gene of interest can be easily measured on the basis of the 
quantifiable amounts of the reporter protein or enzyme. In our setup we utilized a firefly 
luciferase reporter construct, which contained 4 STAT inducible elements (SIE) in front of a 
minimal promoter that drove the expression of the luciferase gene, which contained a protein 
destabilization sequence (Figure 9). Luciferase transcription is induced upon stimulation of 
the JAK/STAT pathway with IL6 or IFN-γ. Due to the utilization of stably transfected 
STAT3 knockout colorectal cancer cell lines (A4 and A4wt) we were able to distinguish 
specific STAT3-driven luciferase transcription, since these cytokines also activate STAT1, 
which also can bind to SIE elements and drive transcription. Next we utilized the pan-JAK 
inhibitor Pyr6 as a negative control, and Stattic, an electrophilic small molecule inhibitor of 
STAT3, as a positive control. These compounds were selected in order to prevent the 
selection of upstream kinase inhibitors. Moreover, the addition of the screening library 
compounds was done one hour after the addition of IL6, again to prevent the selection of 
upstream kinase inhibitors. The rationale behind being phosphatases should have inactivated 
JAK kinases after that time.  
 
Figure 9. High throughput screening setup using cellular STAT3-dependent luciferase 
assay. A. Four SIE elements were cloned in front of a minimal promoter, which drives the 
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transcription of a destabilized luciferase enzyme. Stably transfected cells were then seeded in 
384-well plates. Stattic was used as a positive control of STAT3 inhibition, while Pyr6 was 
used as a negative control in order to exclude upstream kinase inhibition B. Cells were 
stimulated with IL6 for one hour, compounds were added for five hours, followed by 
measurement of luciferase activity. 
 
In Paper I and Paper III this assay was used to identify small molecule inhibitors of STAT3 
(Paper I; Figure 1), and to optimize compound efficiency in the medicinal chemistry 
campaign (Paper III; Figure 1). The initial unforeseen complications with the assays became 
apparent during the course of Paper III. Cellular STAT3 biology appeared to be more 
intricate than was initially expected. STAT3 transcriptional activity was not only regulated 
through the activation of the canonical JAK/STAT pathway. It was elucidated that STAT3 
activity was also constrained by changes in the cellular redox state, which affected STAT3 
directly by oxidation of cysteine thiols on the protein. These findings would advocate for the 
utilization of in vitro experiments in high throughput screenings, in order to find direct 
inhibitors of STAT3. However, both in vitro and cellular assays have different drawbacks that 
should be regarded when conducting small molecule screening campaigns.  
2.2.2 Differential scanning fluorimetry (Paper II) 
The efficacy of a small molecule can be directly related with its ability to bind its target of 
interest. The interaction between small molecule and protein target can be assessed using 
different experimental setups. Differential scanning fluorimetry (DSF) utilizes the 
biophysical principle that ligand binding can increase the inherent thermal stability of a 
protein target. The protein unfolding, which occurs upon gradual heating of the sample can be 
measured with a nonspecific dye, such as Sypro Orange, which starts to fluoresce upon 
binding to hydrophobic surfaces, while in water the fluorescent signal is quenched. 
Measurement of fluorescence on a qRT-PCR, allows for real time tracking of protein 
unfolding (Figure 10). The inflection point of the melting curve is considered the melting 
temperature (Tm), which is used to compare different experimental conditions. After the 
protein has completely unfolded peak fluorescence is achieved upon which the protein starts 
to aggregate and fluorescence starts to decrease over time. Upon binding of a ligand or small 
molecule that binds to the protein of interest, the thermal stability should be increased causing 
a shift in the melting temperature of the protein (ΔTm). 
In Paper II this assay was used to identify the thermal stability of two different STAT3 
protein truncations, in order to pinpoint specificity of phosphopeptides and small molecules 
binding to the STAT3 SH2 domain. However, there are still inherent drawbacks to the 
fundamental concept of the assay. Namely, some ligand-protein interactions do not affect 
thermal stability, which could lead to false negative results. In addition, the proper protein 
folding of recombinant protein is key in order to assess its thermal stability, therefore proper 
verification of protein function and folding using orthogonal methods is essential. Different 
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methods of protein synthesis and purification could affect protein folding and thereby thermal 
stability measurements. 
 
Figure 10. Illustration of DSF protocol A. Samples are heated in a qRT-PCR, where 
simultaneously fluorescence of Sypro Orange is measured. Temperature is gradually 
increased, which induces protein unfolding and Sypro Orange binding to its hydrophobic 
sites. B. The addition of a ligand leads to a shift in the ΔTm of the protein of interest. 
 
2.3 SUMMARY OF RESEARCH PAPERS 
2.3.1 Identification of novel small molecules that inhibit STAT3-dependent 
transcription and function (Paper I) 
The transcription factor STAT3 has been considered a lucrative target for anti-cancer therapy, 
especially since it is activated in many different cancer types. Moreover, it is activated by 
different cytokine and growth factor pathways. STAT3 is activated in the cytoplasm, through 
phosphorylation of tyrosine 705 92. It subsequently translocates to the nucleus where it 
initiates gene transcription by binding specific sequences in their promoter region. STAT3 
target genes promote proliferation, survival, metastasis and immune evasion 28,99. A limited 
amount of STAT3 inhibitors have been tested in early clinical trials, while none have made it 
to later stages 24. Therefore, identification of new small molecule inhibitors could lead to their 
development towards being tested in the clinic.  
STAT3 might be a difficult target due to its 3-dimensional structure. Since it is not a kinase, it 
lacks a commonly targeted ATP-binding pocket or kinase domain. This transcription factor 
mainly has rather big and flat surfaces unfit for small molecule docking 259. It does however 
contain a quite structurally unique SH2 domain and it is believed that small molecules could 
potentially be designed to target this specific site of STAT3. Therefore, in this study, we 
ventured to identify and verify novel small molecules that inhibited STAT3 transcriptional 
activation. 
In order to find novel small molecules, a cell-based high-throughput screening system was 
developed using derived cell lines from DLD1 colon carcinoma cells. The lines A4, with a 
  37 
homozygous STAT3 deletion, and A4wt, A4 cells with reconstituted expression of STAT3 at 
physiological levels. A stable transfected line of A4wt cells expressing a STAT3-reporter 
construct was made. The construct contained 4 SIE binding elements, which drove the 
expression of a destabilized luciferase gene (Figure 9). Luciferase expression was driven by 
STAT3 activation through addition of the cytokine IL6. IL6 stimulated expression of 
luciferase was inhibited by the addition of a pan-JAK inhibitor, Pyr6, and the notorious 
STAT3 inhibitor Stattic. In order to exclude the potential identification of JAK inhibitors (or 
other upstream kinase inhibitors) compounds were added 1h after IL6 addition, which 
effectively prevented Pyr6 inhibition of luciferase expression.  
In total 28.000 compounds were screened, of which 267 were identified hits. Of those, 86 did 
not affect the luciferase assay directly, and 67 were confirmed to have an efficient inhibitory 
dose response. Further chemical analysis and in silico STAT3 SH2 domain docking led to the 
selection of four lead compounds for further characterization in this study (Figure 11A). In 
order to test specific inhibition of STAT3 compared to STAT1, inhibition of IL6-induced 
luciferase by STAT3 was compared to IFN-γ-induced luciferase by STAT1 in respectively 
A4wt and A4. Inhibition of luciferase was similar for KI1, KI4 and KI12. However, KI16 
showed higher propensity towards inhibition of STAT3-driven luciferase transcription. While 
no acute toxicities were noted after the completion of the luciferase assay (5 hours), KI1 and 
KI4 were quite cytotoxic to both A4 and A4wt when assessed after 48 hours. Since both cell 
lines do not depend on STAT3, cytotoxicity was considered an indication of off-target 
effects. 
The quinazolone core structure of both KI1 and KI4 were found to also be present in the 
clinically used drugs Gefitinib, Erlotinib and Vandetanib (Figure 11B). Due to this similarity 
these compounds were suspected to target ATP binding pockets of kinases. It was later 
confirmed that both compounds inhibited phosphorylation of both upstream kinases JAK1 
and JAK2 in A4wt cells (Figure 11C). Only KI16 was able to inhibit IL6-induced STAT3 
phosphorylation in A4wt cells, while none of the compounds affected pSTAT1 either through 
IL6 or IFN-γ induction (Figure 11D). STAT3 mainly drives oncogenic processes though its 
transcriptional function. All four compounds inhibited IL6-driven STAT3 target gene 
expression, while affecting STAT1 target genes to a lesser extent especially for KI12 and 
KI16. Compounds were in general more cytotoxic towards STAT3-dependent compared to 
STAT3-independent cell lines. Interestingly, the compounds affected pSTAT3 levels 
differentially in two lines with constitutive STAT3 activation (MDA-MB468 & DU-145). 
They however did inhibit two target genes and affected migration ability in DU145 cells 
(Figure 11D-E). 
Overall, these four novel compounds were identified using a cell-based high-throughput 
assay for STAT3 transcriptional activity. It was suggested that KI1 and KI4 target upstream 
kinases, while KI12 and KI16 directly target STAT3 by docking into the SH2 domain, 
thereby preventing STAT3 dimerization and transcriptional activity. Inhibition of STAT3 
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activity was further verified by assessment of STAT3 phosphorylation, target gene expression 
as well as STAT3-dependent migration. 
 
Figure 11. Four lead compounds have differential mechanisms of STAT3 inhibition. A. 
Compound structures of KI1, KI4, KI12 and KI16. B. The quinazolone core present in KI1 
and KI4 is also found in different clinically approved kinase inhibitors Gefitinib, Erlotinib 
and Vandetanib. C. KI1 and KI4 inhibit phosphorylation of upstream JAK kinases, thereby 
inhibiting luciferase transcription. KI12 and KI16 do not inhibit upstream kinases and are 
therefore believed to directly inhibit STAT3. D. Only KI16 inhibits STAT3 phosphorylation, 
STAT1 phosphorylation is not affected by any of the compounds. E. STAT3 target gene 
expression is inhibited by all four compounds and Stattic in DU145 cells. STAT3 target gene 
expression was verified by STAT3 knockdown. F. KI12, KI16 and Stattic inhibit cellular 
migration of DU145 cells. 
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2.3.2 STAT3 differential scanning fluorimetry and differential scanning light 
scattering assays: Addressing a missing link in the characterization of 
STAT3 inhibitor interactions (Paper II) 
Many therapeutic agents are under development and many papers continuously report on the 
identification of novel inhibitors of STAT3. These compounds are usually evaluated to be 
STAT3 inhibitors with a certain combination of in silico, in vitro, cellular and often in vivo 
experiments. Some of the established in vitro assays, such as the fluorescence polarization 
assay, electrophoretic mobility shift assay and ELISAs, are often utilized to assess direct 
interaction of an inhibitor with STAT3 protein 223,230,242,244,260. Here we tried to highlight 
some of the shortcomings of some of these methods, through the development of DSF and 
differential scanning light scattering assays (DSLS) for STAT3 inhibitor evaluation.  
First, the specificity of the method had to be evaluated. In order to do so, different STAT3 
protein truncations were generated. STAT3127-688 spanned from the coiled-coil to the SH2 
domain, while STAT3127-468 spanned from the coiled-coil to the DNA binding domain (Figure 
12A). These truncations were selected for their stability and proper folding of the proteins, 
especially since full-length STAT3 protein was found to be very unstable and therefore 
unsuitable for DSF. More importantly, the apparent lack of the SH2 domain of STAT3127-468 
permitted the assessment of specific SH2 domain binders by comparison with STAT3127-688. 
Using different phosphopeptides, gp130, LIFR and STAT3c, specific SH2 domain binding 
was assessed. These peptides were only able to bind to STAT3127-688 or full-length STAT3 in 
fluorescence polarization assays (Figure 12B). Furthermore, specific binding to the SH2 
domain was verified using hydrogen-deuterium exchange (HDX) mass spectrometry.  
All phosphopeptides enhanced thermal stability of STAT3127-688 in concentration-dependent 
manners, while STAT3127-468 thermal stability was unaffected (Figure 12C). The thermal shift 
was determined by the binding affinity of the phosphopeptide, therefore gp130 caused the 
largest and STAT3c the smallest shift, similar to results found in the fluorescence 
polarization assay. Remarkably, four known and widely used STAT3 inhibitors, BP1-102, 
Stattic, STA-21 and S3I-201, either caused a negative thermal shift or did not affect thermal 
stability of both truncations (Figure 12D). All thermal stability results were lastly confirmed 
by nanoDSF and nanoDSLS. 
These last results indicate that the STAT3 inhibitors that are widely used for preclinical 
assessment of STAT3 function might not target STAT3 through their supposed mechanism of 
action of SH2 domain binding. Other papers have also highlighted different mechanisms of 
action of BP1-102, Stattic and S3I-201, indicating that all three contain electrophilic 
properties that cause unspecific irreversible alkylation of protein cysteine residues 243,245,247. 
The development of DSF for STAT3 protein with these two truncations furthermore allows 
for novel high-throughput screening campaigns to identify specific binders of the STAT3 
SH2 domain, which could lead to the identification of novel compounds that might 
specifically target STAT3 function. 
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Figure 12. Utilization of two protein truncations allows the evaluation of specific STAT3 
SH2 domain binders. A. The different domains that are present in the truncations used in 
this study. B. STAT3127-468 was unable to bind a 5-FAM-gp130 peptide not causing any 
change in fluorescence polarization. The other two proteins contained an SH2 domain and 
were able to bind the fluorescent gp130 peptide. C. Different phosphopeptides cause a 
positive thermal shift of STAT3127-688 while not affecting STAT3127-468 thermal stability. D. 
Known STAT3 small molecule inhibitors caused a dose-dependent negative thermal shift of 
both STAT3127-688 and STAT3127-468 or did not affect thermal stability. 
 
2.3.3 Disrupting oncogenic STAT3 activity by targeting TrxR1 with 
irreversible covalent inhibitors (Paper III) 
A select series of compounds was identified in the high-throughput screening from Paper I. 
These 4,5-dichloropyridazanone compounds were further assessed in Paper III. In order to 
further explore these compounds we ventured to optimize activity through a structure-activity 
relationship (SAR) study, which led to the development of in total 70 analogues. Top 
compounds had sub 1 µM IC50 values in the STAT3-dependent luciferase assay also used in 
Paper I (Figure 9). Modifications to the “linker” and “tail” were well tolerated, however 
modifications to the 4,5-dichloropyridazanone moiety were not even slightly tolerated (Figure 
13A). Counter-screens for luciferase enzyme inhibition or cytotoxicity revealed no false 
positive results with any of the tested analogues.  
Four of the most potent compounds were then selected and further assessed (DG-4 to DG-7). 
All compounds were cytotoxic to different cancer cell lines, while less affecting non-
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cancerous cells. The lung adenocarcinoma A549 cells were however found to be the least 
sensitive. The discovery that several widely used STAT3 inhibitors turned out to be 
electrophilic alkylating agents, led us to also test the reactivity of these compounds. Which 
were found to react with GSH. It was feared that these compounds would also inhibit STAT3 
in a more unspecific alkylation of protein cysteine residues, especially since the non-
electrophilic analogues did not affect STAT3-dependent luciferase 243,245,247. In order to 
pinpoint the mechanism of action of this series the “tail” of DG-4 was substituted with a 
fluorescent dansyl moiety, DG-8. DG-8 was able to interact with both STAT3 truncations 
generated in Paper II. However, cell lysate and cellular treatment with DG-8 revealed that it 
specifically bound to a ~55kDa protein (Figure 13B). Therefore, we verified that even though 
our compounds could interact with STAT3, in a cellular setting this did not occur. Hence, we 
set out to discover the cellular protein target. Unfortunately, we were unable to exactly 
pinpoint the protein of interest, however scientific literature revealed a similar compound 
containing a 4,5-dichloropyridazinone group that was identified as a TrxR1 inhibitor. TrxR1 
is a 55kDa protein, additionally containing a highly nucleophilic Sec residue in its active site 
that is very prone to interact with electrophilic moieties. DG-8 was able to bind to reduced 
recombinant TrxR1, and promotion of cysteine insertion in the place of Sec also decreased 
DG-8 binding affinity to TrxR1 in cells. Competition assays with top compounds and 
identified TrxR1 inhibitors showed the ability of DG-4, DG-5, DG-6, TRi-1, Stattic and 
Auranofin to potently outcompete DG-8 in cells. The less potent compound DG-7 as well as 
TRi-3 was only able to outcompete DG-8 at high concentrations. Interestingly, TRi-2, which 
is believed to not target the Sec residue but rather the FAD moiety of TrxR1, was unable to 
outcompete DG-8 further confirming the specific targeting of the Sec residue by the DG 
compounds.  
Next, we explored the inhibitory effects of the compounds on TrxR1 function. Compounds 
DG-4 and DG-5 were potent inhibitors of cellular TrxR1, while DG-6 and Stattic inhibited 
approximately 40% of total TrxR1 activity (Figure 13C). Lastly, DG-7 and BP1-102 did not 
affect cellular TrxR1 activity. Interestingly, the ability to inhibit cellular TrxR1 corresponded 
to the ability of the compounds to outcompete DG-8. All compounds were unable to inhibit 
TrxR1 function in the absence of NADPH, similar to the inability of DG-8 to bind to 
oxidized TrxR1. Moreover, compound binding to the TrxR1 Sec residue led to the formation 
of SecTRAPs, which are known to create additional intracellular reactive oxygen species. In 
addition, we were able to show that four known TrxR1 inhibitors were also able to inhibit 
STAT3-dependent luciferase.  
Interestingly, compound treatment caused Prx2 and STAT3 oxidation (Figure 13D). This was 
previously shown to be a mechanism of STAT3 transcriptional inactivation 149. The induction 
of oxidative stress caused by compound treatment leads to oxidation of Prx2 that can relay 
oxidative equivalents to STAT3 (Figure 6). TrxR1 is the reductase that keeps Prx2 and 
STAT3 reduced by consuming NADPH. Our compounds however inhibit TrxR1 leading to a 
halt in the reduction of the relay, thereby causing Prx2 and STAT3 oxidation, which is further 
exacerbated by SecTRAP formation. Lastly, compound cytotoxicity was potentiated 
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approximately 5-fold by buthionine sulfoximine (BSO) treatment. BSO inhibits the synthesis 
of GSH, leading to cellular GSH depletion. This indicated that cytotoxicity was caused by 
induction of oxidative stress. 
Altogether, our data suggest that the top DG compounds are potent inhibitors of TrxR1, and 
TrxR1 inhibition could cause additional cellular ROS generation, which in turn oxidizes Prx2 
and STAT3 inhibiting its transcriptional activity. These results were strengthened by the 
observation that other widely used STAT3 inhibitors also inhibited TrxR1 function, while 
several known TrxR1 inhibitors were also able to inhibit STAT3 transcriptional activity.  
 
Figure 13. 4,5-dichloropyridazinone compounds inhibit STAT3 through inhibition of 
TrxR1 causing STAT3 inactivation through its oxidation A. Summary of SAR study, 
modifications to the dichloropyridazinone were found to be generally unfavorable and led to 
the loss of STAT3 inhibition. Modifications to the “linker” were able to increase compound 
potency, especially by the introduction of electron-withdrawing groups to the nitrogen at the 
two position of the pyridazinone ring. Modifications to the “tail” were well tolerated and 
allowed for the appendage of a dansyl fluorescent group to the compound, without significant 
loss of cellular permeability and inhibition potency. B. Instead of binding to STAT3 in a 
cellular setting, the fluorescent DG-8 bound a singular 55kDa protein in A549 cells. This 
protein was confirmed to be TrxR1. C. Top compounds are potent inhibitors of cellular 
TrxR1. D. Top compounds cause oxidation of both Prx2 and STAT3, causing STAT3 to no 
longer be transcriptionally active and drive expression of its target genes. 
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2.4 DISCUSSION & IMPLICATIONS 
The papers enclosed in this thesis are purely dedicated to the STAT3 small molecule inhibitor 
field. This was initiated by the observations and conclusions we made in Paper I. We were 
able to identify novel small molecule inhibitors of STAT3 function, and could provide both 
in vitro as well as cellular data to confirm STAT3 inhibition. However, we lacked target 
engagement experiments in a cellular setting. Therefore, we tried to highlight the importance 
of result translation from in vitro to cellular data in Paper II & Paper III. We focused on 
novel in vitro method development in Paper II, which could be utilized for the development 
of novel direct STAT3 inhibitors. In Paper III we focused on compound target and 
mechanism of action elucidation, where we were able to pinpoint a target in a cellular setting 
that could directly affect STAT3 function. The cellular function of our target, TrxR1, and its 
effects on other cellular functions could also be explored further. Future work could focus on 
two main areas. The further development and identification of novel direct STAT3 inhibitors, 
more specifically SH2 domain binders of STAT3. On the other hand, the TrxR1 or Trx 
pathway function and its effects on STAT3, other transcription factors and cellular functions 
could be further assessed.  
Several novel methods have been developed in recent years to explore protein target 
engagement. One of the more repeatedly used is the cellular thermal shift assay (CETSA). 
CETSA is based on the same concept as DSF that ligand or small molecule binding can shift 
protein thermal stability (Paper II). The clear advantage of CETSA is that target engagement 
can be assessed in cells, in vivo and the method has been optimized to also be performed in 
high throughput 261–263. It has further been combined with mass spectrometry in order to 
analyze thermal stability of many different cellular proteins in the same biological sample 264. 
These different methods could be readily used to determine the protein target and specificity 
of the KI compounds of Paper I, and could further explain the differences in mechanism of 
action. The potential drawback to this method could be that different post-translational 
modifications indirectly caused by small molecule compounds potentially also influence 
protein thermal stability. This could convolute the results, especially when the target protein 
is unknown. 
STAT3 is not the only protein that becomes oxidized during cellular oxidative stress. As 
described before, the transcription factor pathways of Nrf2 and NF-κB are also redox 
regulated through different mechanisms 200,204,214. A comprehensive list of proteins that are 
oxidized by different Prxs during H2O2 exposure was recently published, where oxidized 
proteins were captured using a recombinant human Trx1 trapping mutants 150. ASK1, annexin 
A2, cystathionine β-synthase, STAT3 and different heat shock proteins among approximately 
40 proteins were identified as substrates of Prx1, Prx2 and Trx1 by tryptic peptide mass 
spectrometry. This is an indication that only a select group of proteins is prone to oxidation. 
However, direct oxidation of proteins should not be disregarded. These proteins might not 
have been identified using this method. An overall decrease in protein thiol oxidation 
however was observed in dual Prx1/Prx2 knockout and knockdown cell lines. The effects of 
the DG compounds (Paper III) on the transcriptional function of Nrf2 and NF-κB should be 
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tested. And the function of the other identified protein substrates of Prxs should also be 
assessed for their importance in cancer development and potential off-target effects. Perhaps 
specific targeting of TrxR1 is the way forward to inhibit STAT3 in tumor cells. TRi 
compounds are actively being optimized for clinical application, and therefore time will tell if 
they also can be used as clinical drugs. There might be a role for TrxR1 inhibitors in the 
clinic, very recently APR-246 was FDA approved for treatment of patients with TP53 mutant 
MPN. APR-246 has been described to reactive mutant p53 and trigger apoptosis in tumor 
cells, however it was also shown to inhibit TrxR1 irrespective of p53 status 265,266.  
At the start of this thesis the importance of cellular redox signaling for STAT3 function had 
just become apparent 149. Several STAT3 small molecule inhibitor papers acknowledge the 
effects their compounds have on cellular redox balance, and often highlight the importance of 
STAT3 for mitochondrial function and therefore direct inhibition of STAT3 might affect the 
cellular redox balance 239,255. One recent study however focused on cancer cell metabolism 
and mitochondrial function 256. The authors highlighted the importance of a metabolic switch 
to oxidative phosphorylation as a key driver for cancer cells to acquire resistance to a wide 
range of oncogene-targeted therapies, which has moreover been shown to cause STAT3 
activation 100–105. More interestingly is that they identified OPB-51602, one of the most recent 
and promising STAT3 inhibitors in early clinical trials, as a specific inhibitor of oxidative 
phosphorylation. OPB-51602 was identified as a specific inhibitor of mitochondrial complex 
I activity at nanomolar concentration. Other oxidative phosphorylation inhibitors have also 
been identified as inhibitors of STAT3 activity. Analysis of a 12-gene STAT3 activation 
signature, revealed Atovaquone as a potent inhibitor of STAT3 transcriptional activity 267. 
Atovaquone is an aromatic compound known as a quinone, which are used as antimicrobials 
and also have antitumor activity. Many quinones were shown to also inhibit TrxR1 and cause 
the formation of SecTRAPs 199. These observations draw a link between the effects of cellular 
redox, metabolism and STAT3 function. It would be very interesting to further explore the 
cellular targets of these compounds, and clearly delineate the causes of the observed effects 
of many electrophilic and other compounds.  
The intricacies of STAT3 biology are becoming more and more apparent over the years, and 
especially with the number of published small molecule inhibitors of STAT3. The shear 
number of claimed STAT3 inhibitors that are being continuously published could however 
counteract the potential of one being selected and pushed towards clinical trial. It is painful to 
see that none have made it to a clinical application and it is testament to the degree of 
difficulty of specific STAT3 targeting. This might unfortunately also deter potential new 
exploits of reaching this esteemed goal. However, several academic and commercial ventures 
are not deterred and keep working towards reaching it.  
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